Galmed Pharmaceuticals Stock Revenue
| GLMD Stock | USD 2.76 0.06 2.13% |
Galmed Pharmaceuticals fundamentals help investors to digest information that contributes to Galmed Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Galmed Stock. The fundamental analysis module provides a way to measure Galmed Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Galmed Pharmaceuticals stock.
Galmed |
Galmed Pharmaceuticals Company Revenue Analysis
Galmed Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Galmed Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Galmed Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galmed Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Galmed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Galmed Pharmaceuticals by comparing valuation metrics of similar companies.Galmed Pharmaceuticals is currently under evaluation in revenue category among its peers.
Galmed Fundamentals
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (7.93 M) | ||||
| Shares Outstanding | 1.66 M | ||||
| Shares Owned By Insiders | 1.28 % | ||||
| Shares Owned By Institutions | 0.48 % | ||||
| Number Of Shares Shorted | 6 K | ||||
| Price To Earning | (6.79) X | ||||
| Price To Book | 0.25 X | ||||
| EBITDA | (6.87 M) | ||||
| Net Income | (6.91 M) | ||||
| Cash And Equivalents | 22.4 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 41 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.48 X | ||||
| Book Value Per Share | 33.01 X | ||||
| Cash Flow From Operations | (6.14 M) | ||||
| Short Ratio | 0.27 X | ||||
| Earnings Per Share | 69.72 X | ||||
| Target Price | 12.0 | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 4.67 M | ||||
| Total Asset | 16.63 M | ||||
| Retained Earnings | (192.95 M) | ||||
| Working Capital | 10.49 M | ||||
| Current Asset | 23.38 M | ||||
| Current Liabilities | 2.54 M | ||||
| Net Asset | 16.63 M |
About Galmed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Galmed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galmed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galmed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:Check out Galmed Pharmaceuticals Piotroski F Score and Galmed Pharmaceuticals Altman Z Score analysis. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.